Latest / Bloomberg Intelligence / Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat

Transcript

Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat · Bloomberg Intelligence

• 0:02
  Speaker 1: Bloomberg Audio Studios, Podcasts, radio news. You're listening to the
• 0:10
  Speaker 1: Bloomberg Intelligence Podcast. Catch us live weekdays at ten am
• 0:14
  Speaker 1: Eastern on Applecarclay, and Android Auto with the Bloomberg Business App.
• 0:18
  Speaker 1: Listen on demand wherever you get your podcasts, or watch
• 0:21
  Speaker 1: us live on YouTube.
• 0:23
  Speaker 2: Eli Lilly, it.
• 0:25
  Speaker 3: Had a salespaper. Shares are taken ahead, Yeah, Lily shares
• 0:28
  Speaker 3: it down about fourteen percent. There is something overshadowing that.
• 0:31
  Speaker 3: For that, we're going to bring in Damien Gardett's Bloomberg
• 0:33
  Speaker 3: News health reporter. Damian, thanks for joining us here in
• 0:37
  Speaker 3: the studio. So it looks like this experiment, this drug experiment,
• 0:41
  Speaker 3: the weight loss pill, and that's the thing here. It
• 0:43
  Speaker 3: didn't do as well in the study as Wall Street had.
• 0:46
  Speaker 4: Expected exactly so it met its goals and it helped
• 0:50
  Speaker 4: people lose weight, which was the whole point of it.
• 0:51
  Speaker 4: This was enrolling people with obesity, but that weight loss
• 0:55
  Speaker 4: was about eleven percent of body weight, and Wall Street
• 0:58
  Speaker 4: was hoping to see something more kin to fourteen to
• 1:01
  Speaker 4: fifteen percent, which would match what's seen with the injectible
• 1:05
  Speaker 4: GLP one weight loss medicines like with GOVI from rival
• 1:08
  Speaker 4: Novo Nordisk. So despite the trial being a success, and
• 1:11
  Speaker 4: despite this pill seemingly on the path to winning FDA
• 1:14
  Speaker 4: approval and hitting the market as early as next year,
• 1:17
  Speaker 4: the reaction, as you mentioned, was dramatically negative formulaly because these,
• 1:22
  Speaker 4: you know, single digit percentage differences are perceived to be
• 1:25
  Speaker 4: massively important to the ultimate financial future. It's medicine.
• 1:29
  Speaker 5: Here's the thing for me knowing someone that does this
• 1:32
  Speaker 5: GLP one thing, whatever it is. You gotta reduce the
• 1:37
  Speaker 5: side effects of the nausea, and this one didn't. And
• 1:40
  Speaker 5: that was the I know people that use it and
• 1:43
  Speaker 5: use the injection or saying, boy, when the oral one
• 1:45
  Speaker 5: comes out, I'm told that the side effects will be
• 1:49
  Speaker 5: dramatically less, which is a huge selling point, and I
• 1:52
  Speaker 5: guess that's not what they saw here.
• 1:54
  Speaker 4: Basically, in this study, they saw gastro intestinal side effects
• 1:57
  Speaker 4: that were comparable to the injectible one, which your point
• 2:00
  Speaker 4: could be viewed as a negative. There was a I
• 2:02
  Speaker 4: think there was a home run scenario where Lily's pill
• 2:05
  Speaker 4: would both lead to a greater percentage of body weight
• 2:07
  Speaker 4: loss and as you mentioned, have fewer of the nausea
• 2:11
  Speaker 4: vomiting field.
• 2:12
  Speaker 5: Plus that were we being the pharmaceutical biotech, and we're
• 2:15
  Speaker 5: in the early innings of this GLP type obesity thing.
• 2:20
  Speaker 5: I can't imagine why it's not going to get better
• 2:22
  Speaker 5: and better and better and better, or I don't know
• 2:24
  Speaker 5: the science. Maybe we're already at that limit. We are
• 2:27
  Speaker 5: at the limit of this whatever this thing is.
• 2:29
  Speaker 4: I don't think so. I mean, in granted, you know
• 2:31
  Speaker 4: clinical trials need to play out. Science biology famously unpredictable,
• 2:34
  Speaker 4: but I would say the space is moving in two directions.
• 2:37
  Speaker 4: One combination medicines that add GLP one to other things
• 2:40
  Speaker 4: that can lead to more dramatic weight loss, and then
• 2:42
  Speaker 4: two more convenient things like pills that you can take
• 2:45
  Speaker 4: that maybe don't have the same effect on body weight,
• 2:48
  Speaker 4: but that would be cheaper to manufacture, presumably cheaper to
• 2:50
  Speaker 4: acquire for patients because these injectables have list prices of
• 2:54
  Speaker 4: inexcess of one thousand dollars a month. So in the
• 2:57
  Speaker 4: best case scenario, let's say five years from now, there
• 2:59
  Speaker 4: will be an armamentarium of weight loss medicines. If you
• 3:03
  Speaker 4: an armamentarium, which I think I stumbled over a whole
• 3:05
  Speaker 4: bunch of them, like in an armory. Let's say so
• 3:08
  Speaker 4: a physician yes, a physician, could you know, diagnose a
• 3:11
  Speaker 4: patient and say, for some people you will need an
• 3:14
  Speaker 4: injectable that you can lose twenty five percent of your
• 3:16
  Speaker 4: body weight on. For some people you may be good
• 3:18
  Speaker 4: with an oral medicine where you lose a single digit
• 3:20
  Speaker 4: or even ten percent of your body weight, or mixing
• 3:23
  Speaker 4: and matching using one for maintenance and the upside being
• 3:26
  Speaker 4: theoretically this will one become a massive one hundred billion
• 3:29
  Speaker 4: dollar market for the pharmaceutical industry, but two have knock
• 3:32
  Speaker 4: on beneficial effects for people's health.
• 3:34
  Speaker 3: So where do we stand with the pills? I mean,
• 3:36
  Speaker 3: what other competition is out there? Who else is working
• 3:39
  Speaker 3: on one that we should keep an eye on as well.
• 3:41
  Speaker 4: So Novo Nordisk has an oral version of the injectable
• 3:44
  Speaker 4: week govy. It is not as convenient or I would
• 3:49
  Speaker 4: say innovative frankly, as Lily's pill, because it's basically just
• 3:52
  Speaker 4: a bunch of wgovy shoved into a tablet that you
• 3:55
  Speaker 4: eat and it sits in your gut and administers the
• 3:57
  Speaker 4: drug there. And that it comes with restriction. You can't
• 4:00
  Speaker 4: take it with food, you have to do it in
• 4:01
  Speaker 4: the morning. It's not really as attractive a commercial product,
• 4:04
  Speaker 4: I think it's fair to say as Lilies, but there
• 4:07
  Speaker 4: are other oral options from smaller biotech companies that we
• 4:11
  Speaker 4: may see them progress to the market. There's also a
• 4:14
  Speaker 4: lot of m and a speculation around these firms that
• 4:16
  Speaker 4: a company like Pfizer, for example, which kind of crashed
• 4:19
  Speaker 4: and burned with its first attempt to make a GLP
• 4:21
  Speaker 4: one pill, might acquire them. So this is very much
• 4:24
  Speaker 4: a space to watch. I would say a year from now,
• 4:26
  Speaker 4: it's quite likely that it will look demonstrably different than
• 4:28
  Speaker 4: it looks right now.
• 4:29
  Speaker 5: So as I look at the PGeo table, which kind
• 4:32
  Speaker 5: of breaks down where the revenue comes from Lily, where
• 4:36
  Speaker 5: is the cardio metabolic health is at the sector again,
• 4:39
  Speaker 5: now that's that sector is sixty five percent of total revenue.
• 4:43
  Speaker 5: So that's a big deal for Lily.
• 4:45
  Speaker 4: And that's not inclusive of this oral drug which isn't
• 4:48
  Speaker 4: even approved yet. So I mean, as you mentioned these
• 4:50
  Speaker 4: data overshadowing, Lily had like a blowout quarter. They're approved
• 4:53
  Speaker 4: medicine for obesity and the same thing is sold for diabetes.
• 4:57
  Speaker 4: Both of them beat estimates, they raised revenue guide and
• 5:00
  Speaker 4: profit guidance. They're doing very very well, but I think
• 5:03
  Speaker 4: the stock reaction today is sort of an illustration of
• 5:05
  Speaker 4: just how much is baked into the potential of these medicines.
• 5:09
  Speaker 4: Lily has flirted with being a trillion dollar valuation company.
• 5:12
  Speaker 4: They're not there anymore, but that's strictly a reflection of
• 5:15
  Speaker 4: what people believe will come of this class of medicine.
• 5:18
  Speaker 3: So, speaking of the potential, then, so why is the
• 5:20
  Speaker 3: science behind these pills? Why is it such a challenge.
• 5:24
  Speaker 4: I mean, getting what you can do in an injectable medicine,
• 5:28
  Speaker 4: getting that down into a pill has been deviled the
• 5:31
  Speaker 4: drug industry for many, many years because there are safety concerns,
• 5:35
  Speaker 4: there are dosing concerns. The ideal product is like a
• 5:38
  Speaker 4: superpill that prolongs your life and et cetera. But there's
• 5:41
  Speaker 4: a reason we have so few of those, and it's
• 5:44
  Speaker 4: basically just the trial and error and the unpredictability of biology.
• 5:48
  Speaker 4: And I think these companies are always trying to bend
• 5:50
  Speaker 4: the curves of failures. But like it remains true that
• 5:52
  Speaker 4: roughly one in ten medicines actually makes it from the
• 5:55
  Speaker 4: lab to the pharmacy.
• 5:57
  Speaker 5: My freshman year college chemistry lab partner went on to
• 6:03
  Speaker 5: become like this crazy smart dude played a wide receiver
• 6:08
  Speaker 5: in the NFL. Then he became a signist an astronaut
• 6:13
  Speaker 5: space shuttle crazy and I was like, I was like, dude,
• 6:17
  Speaker 5: can you carry me in this chemistry classic because I'm
• 6:19
  Speaker 5: not really into it? And he was super smart. So
• 6:23
  Speaker 5: and then that he didn't peak there, he didn't He
• 6:24
  Speaker 5: didn't peak in the NFL. I guess he peaked the
• 6:26
  Speaker 5: flying around in space.
• 6:27
  Speaker 1: So good.
• 6:28
  Speaker 5: There. What's the next thing that you're looking for in
• 6:31
  Speaker 5: a pharmer's space here? What's the next big mover here
• 6:34
  Speaker 5: on a company level that you're looking.
• 6:35
  Speaker 4: At for weight loss specifically or just more broadly.
• 6:39
  Speaker 5: Yeah, I think everything.
• 6:41
  Speaker 4: Actually MRK is working on. Speaking of pills, they're working
• 6:44
  Speaker 4: on a pill version that would be basically a superstat
• 6:47
  Speaker 4: It would lower bad cholesterol to a level that cannot
• 6:51
  Speaker 4: be done with oral medicines that exists right now, and
• 6:55
  Speaker 4: that it kind of follows this same trajectory that I
• 6:58
  Speaker 4: think we're seeing big pharma company years ago after statinshe
• 7:01
  Speaker 4: generic kind of moved away from primary care medicines because
• 7:04
  Speaker 4: it's difficult, you have to run big trials, it's expensive.
• 7:06
  Speaker 4: If they fail, you lose a lot of money. And
• 7:08
  Speaker 4: move toward oncology and rare diseases. I feel like we're
• 7:11
  Speaker 4: seeing and I think GLP one was sort of the
• 7:13
  Speaker 4: trojan horse in some ways of this. We're seeing the
• 7:15
  Speaker 4: major drug companies move back toward primary care, trying to
• 7:18
  Speaker 4: invent medicines that would be taken by millions of people
• 7:20
  Speaker 4: and they would actually address the number one killer of Americans,
• 7:22
  Speaker 4: which is heart disease. So I think that's a trend
• 7:24
  Speaker 4: that I'm following, and we'll get data from that murk pill,
• 7:26
  Speaker 4: I believe by the end of the year.
• 7:28
  Speaker 5: All Right, I mean you and Sam Fizzelli, you guys,
• 7:30
  Speaker 5: do whatever you do in that healthcare thing. Just tell
• 7:31
  Speaker 5: us when something important is happening. Damien Gardelli, a healthcare
• 7:34
  Speaker 5: reporter for Bloomberg News, joinings life here in our Bloomberg
• 7:36
  Speaker 5: Interactive Broker studio. You know, back in my trading days, man,
• 7:40
  Speaker 5: I'd go to my healthcare guy, I say, hey, can
• 7:43
  Speaker 5: I buy Lily today? It's down fifteen percent. I mean,
• 7:46
  Speaker 5: it feels like an entry point to me, and hopefully
• 7:49
  Speaker 5: Mianas will have a good idea what's going on space.
• 7:51
  Speaker 3: I mean, you hear the GLP ones are supposed to
• 7:53
  Speaker 3: lower cholesterol, but then you have other He was just
• 7:55
  Speaker 3: talking about another cholesterol, yes, and coming out.
• 7:57
  Speaker 5: But I mean these GLP things have been I see
• 8:01
  Speaker 5: a new story every day. How they help this, they
• 8:03
  Speaker 5: cure this, they lowered the risk of this. It's not
• 8:05
  Speaker 5: just so I don't know what's going. Healthcare space is
• 8:09
  Speaker 5: a tough, tough one to invest in. I think that's
• 8:12
  Speaker 5: why there's mds and PhDs all over the place in
• 8:17
  Speaker 5: investment firms investing in that space.
• 8:20
  Speaker 1: You're listening to the Bloomberg Intelligence Podcast. Catch us live
• 8:24
  Speaker 1: weekdays at ten am Eastern on Applecarplay and Android Auto
• 8:27
  Speaker 1: with the Bloomberg Business App. Listen on demand wherever you
• 8:30
  Speaker 1: get your podcasts, or watch us live on YouTube.
• 8:34
  Speaker 5: Almost the last time you went to a movie at
• 8:35
  Speaker 5: a movie theater, oh, it was a.
• 8:37
  Speaker 3: Tough We were supposed to go to the other weekend
• 8:39
  Speaker 3: and see like Superman, but that didn't happen. I watch
• 8:42
  Speaker 3: a lot of them, like I stream them, like for example, Minecraft,
• 8:45
  Speaker 3: like I saw at home and then I didn't go
• 8:47
  Speaker 3: to the theater to see it. Right, that's what like
• 8:49
  Speaker 3: Warner Brothers is dealing.
• 8:50
  Speaker 5: Yeah, exactly right, So but I'm Warner Brothers Discovery they
• 8:53
  Speaker 5: put out results. I don't know. I mean, my expectations
• 8:56
  Speaker 5: are really low for this company, but they I thought
• 8:59
  Speaker 5: they were pretty decent stocks. Trading off a little bit here,
• 9:02
  Speaker 5: let's get the latest on what's happening at One Brother's
• 9:04
  Speaker 5: Discovery and even maybe a little bit on our friends
• 9:06
  Speaker 5: at Peloton. Jen Sherman's my buddy there. She's a person
• 9:09
  Speaker 5: I drink with. Of course, either wrong anah in us.
• 9:12
  Speaker 5: I'm not gonna do it with some dude. I mean,
• 9:13
  Speaker 5: you know, why would you do that. She's your friend
• 9:15
  Speaker 5: in your head exactly exactly where friends so githerrang and nothing.
• 9:18
  Speaker 5: She actually is the analyst on all this media stuff.
• 9:21
  Speaker 5: She's down there in our Princeton University sprawling campus. Hey, Gaeta,
• 9:26
  Speaker 5: talk to us about Warner Brothers Discovery, because there are
• 9:28
  Speaker 5: like a lot of traditional media comedies trying to make
• 9:30
  Speaker 5: that transition from the good old days of linear television,
• 9:34
  Speaker 5: cable television, all that kind of stuff to the streaming world.
• 9:37
  Speaker 5: What did you learn from Warner Brother's Discovery.
• 9:40
  Speaker 2: Yeah, so, Paul, what we really saw was, you know,
• 9:43
  Speaker 2: a continuation of the same. So the streaming business is
• 9:45
  Speaker 2: doing really well. The studio business is doing extremely well.
• 9:49
  Speaker 2: But TV Networks, which is really eighty percent off their ibadah,
• 9:53
  Speaker 2: is still struggling, and we saw a twenty five percent
• 9:55
  Speaker 2: slump in their TV Networks ibadah. So you know, that
• 10:00
  Speaker 2: continues to be a pain point. And while there was
• 10:02
  Speaker 2: initially some you know, obviously some excitement about the turnaround
• 10:07
  Speaker 2: and both the streaming and the studio businesses, the fact
• 10:10
  Speaker 2: that there is absolutely no respite inside for TV is
• 10:14
  Speaker 2: extremely distressing and that's.
• 10:15
  Speaker 3: Why their shares are down like seven percent. Okay, So
• 10:18
  Speaker 3: talk to me about the companies in the process of
• 10:21
  Speaker 3: splitting itself into two separate entities, right, So where do
• 10:24
  Speaker 3: we stand with that? What are the pros and cons
• 10:26
  Speaker 3: that go along with that?
• 10:28
  Speaker 2: Yeah, so this is you know, one of the best
• 10:30
  Speaker 2: ways for them, or at least you know, the fact
• 10:34
  Speaker 2: that they've kind of decided to do this really follows
• 10:36
  Speaker 2: a pattern in most of the media landscape where they're selling.
• 10:39
  Speaker 2: They're kind of separating the low growth assets from the
• 10:42
  Speaker 2: slightly higher growth assets. The low growth or the low
• 10:44
  Speaker 2: growth assets being the TV business. That for Warner Brothers,
• 10:48
  Speaker 2: that split will happen in the middle of next year,
• 10:52
  Speaker 2: and really the strategy here is to unlock shareholder value
• 10:56
  Speaker 2: because you know that, you know, they combine their Warner
• 10:58
  Speaker 2: Brothers business with a Discovery you know networks. Of course
• 11:03
  Speaker 2: that really hasn't gone anywhere. And so finally everybody in
• 11:07
  Speaker 2: the in the in the media world is doing this
• 11:09
  Speaker 2: where they're kind of separating out the secularly challenged TV networks.
• 11:13
  Speaker 6: Uh.
• 11:13
  Speaker 2: The only problem here is that we still really don't
• 11:16
  Speaker 2: have a very clear strategy. So they have to really
• 11:18
  Speaker 2: outline that, and I think that is part of the
• 11:20
  Speaker 2: reason why we're also kind of seeing this the decline
• 11:23
  Speaker 2: and shares this morning.
• 11:25
  Speaker 5: All Right, they had the studio had a good quarter here,
• 11:29
  Speaker 5: a couple in some some hits like Sinners, a Minecraft movie,
• 11:33
  Speaker 5: Final Destination, Bloodlines and things like that. Talk to us
• 11:35
  Speaker 5: about the studio and maybe it's kind of it's forward slate.
• 11:39
  Speaker 5: How does that look for the company?
• 11:41
  Speaker 2: The forward say it, Actually, it looks really good, Paul.
• 11:43
  Speaker 2: You know, they just had their major DC reboot with Superman. Uh,
• 11:48
  Speaker 2: and they're what they're really trying to do now going forward.
• 11:51
  Speaker 2: I mean, they didn't have a Superman movie for years.
• 11:53
  Speaker 2: Their DC strategy was in a mess. You know, it
• 11:55
  Speaker 2: was a mess. They had so many movies out there,
• 11:58
  Speaker 2: it was all confusing lines. But I think finally they've
• 12:02
  Speaker 2: kind of they're going to write that ship. So they've
• 12:04
  Speaker 2: committed to a pretty strong slate of about twelve to
• 12:07
  Speaker 2: fourteen movies going forward. The big thing for them is
• 12:12
  Speaker 2: to really get Studio EBITDA to about three billion dollars,
• 12:15
  Speaker 2: and they seem to be well on their way. I mean,
• 12:17
  Speaker 2: last year was a complete mess. This year definitely much
• 12:20
  Speaker 2: much better. They're actually if you just look at box
• 12:23
  Speaker 2: office performance overall, they already have about a twenty five
• 12:26
  Speaker 2: twenty six percent share of the domestic box office, so
• 12:29
  Speaker 2: they're only very slightly behind Disney. So they're definitely doing
• 12:32
  Speaker 2: well and their strategy is working. They have a pretty
• 12:34
  Speaker 2: good content pipeline.
• 12:36
  Speaker 3: All right, let's switch over at Peloton. How is this
• 12:38
  Speaker 3: company doing? I mean, is there subscribers? Are they continuing
• 12:41
  Speaker 3: to come in? Are people still using this equipment as
• 12:44
  Speaker 3: much as they used to?
• 12:47
  Speaker 2: So for Peloton, really and the story has not been
• 12:51
  Speaker 2: so much on subscribers, unfortunately. It has really been more
• 12:54
  Speaker 2: about trimming the fat literally at the company and kind
• 12:59
  Speaker 2: of getting profits into full focus. And if you just
• 13:01
  Speaker 2: saw this quarter's results and what they reported for the
• 13:03
  Speaker 2: full year. For fiscal twenty twenty five, I mean, the
• 13:07
  Speaker 2: progress that they've made in terms of profitability has been
• 13:10
  Speaker 2: absolutely outstanding. So they reported adjusted IBADAH that came in
• 13:14
  Speaker 2: about nineteen twenty percent higher than guidance and consensus their
• 13:19
  Speaker 2: forward guidance, So fiscal twenty twenty six suggested EBITDA guidance
• 13:23
  Speaker 2: is also was also way above consensus. So the way
• 13:26
  Speaker 2: that they're kind of optimizing their operating expenses has been
• 13:29
  Speaker 2: absolutely stellar. You know, just everything in terms of workforce reduction,
• 13:33
  Speaker 2: in terms of inventory management, you know, op X costs,
• 13:37
  Speaker 2: marketing expenses, everything has been absolutely top notch. The only
• 13:41
  Speaker 2: problem for them is reintegrating demand. And that's where you know,
• 13:45
  Speaker 2: we're kind of really kind of seeing this disconnect because
• 13:48
  Speaker 2: the financial metrics are really good, but the subscriber metrics,
• 13:52
  Speaker 2: unfortunately are not.
• 13:54
  Speaker 5: Is there a credible plan there to reignite growth there?
• 13:58
  Speaker 5: I just kind of it feels like, you know, everybody
• 14:01
  Speaker 5: who's got one's got one. How did they think talk
• 14:05
  Speaker 5: about that part of the story.
• 14:07
  Speaker 2: Yeah, so it's really going to be a little bit hard.
• 14:10
  Speaker 2: I mean, yeah, on the margin, I think they can
• 14:11
  Speaker 2: do some things to kind of reignite a little bit
• 14:14
  Speaker 2: of the hardware sales, but in terms of a sustainable
• 14:17
  Speaker 2: go forward strategy that is really still pretty unclear. Paul, So,
• 14:20
  Speaker 2: I think right now, what they're really trying to do
• 14:22
  Speaker 2: is again really get you know, more costs out of
• 14:26
  Speaker 2: the system, maybe increase subscription prices a little bit, so
• 14:30
  Speaker 2: kind of pad that top line a little bit. But
• 14:33
  Speaker 2: in terms of you know, the overall subscription growth story,
• 14:36
  Speaker 2: I'm not so sure that's really going to be a
• 14:39
  Speaker 2: volume story. I think it's it's going to you know,
• 14:42
  Speaker 2: focus more on kind of rates and price and improving
• 14:45
  Speaker 2: pricing and either how much.
• 14:46
  Speaker 3: Of that, you know, cutting costs includes cutting jobs.
• 14:50
  Speaker 2: Yeah, they did actually you know, announce a six percent
• 14:53
  Speaker 2: workforce reduction as well, so a lot of it is
• 14:56
  Speaker 2: going to come down to cutting jobs.
• 14:58
  Speaker 5: All right, Just one quick thing on Warner Brothers Discovery.
• 15:01
  Speaker 5: What's the timing of this separation it's.
• 15:04
  Speaker 2: Going to So they announced the formal plan in June.
• 15:07
  Speaker 2: It's going to happen by Midge twenty twenty six, so
• 15:10
  Speaker 2: by middle of next year.
• 15:12
  Speaker 5: Okay, all right, we'll keep an eye on that. Gith
• 15:14
  Speaker 5: Throng and at and she covers all the media stuff
• 15:17
  Speaker 5: for Bloomberg intelligence down there for them to display.
• 15:20
  Speaker 3: I mean, you see Comcasts do it right.
• 15:21
  Speaker 5: Yeah, I think it is simply because you hope that
• 15:25
  Speaker 5: the two parts have more total value than they do together,
• 15:29
  Speaker 5: and so you're concerned that the high growth business is
• 15:32
  Speaker 5: being pulled down by the slower growth cable networks. So
• 15:36
  Speaker 5: you split them out and see how far this, you know,
• 15:39
  Speaker 5: the streaming business in the studio can fly, I guess
• 15:42
  Speaker 5: is kind of the thought there. So we see it
• 15:44
  Speaker 5: all the time and lots of different industries, and there
• 15:47
  Speaker 5: was a time, you know, when all these assets made
• 15:50
  Speaker 5: sense to be together. But the fortunes, the economic fortunes
• 15:53
  Speaker 5: of the cable network and broadcast network business have been
• 15:56
  Speaker 5: permanently damaged, and it gets worse every year. So you know,
• 16:01
  Speaker 5: you just got to cut those out and see how
• 16:03
  Speaker 5: they trade on a standalone basis. Maybe ultimately they get acquired,
• 16:07
  Speaker 5: or maybe some of these networks maybe get together the
• 16:09
  Speaker 5: Comcast stuff. Maybe we'll get together with the Warner brother
• 16:12
  Speaker 5: stuff and just become bigger and get some cross energy.
• 16:15
  Speaker 5: So we'll see how that plays out. But we're seeing
• 16:17
  Speaker 5: that across the media space.
• 16:18
  Speaker 6: Here.
• 16:20
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 16:24
  Speaker 1: weekdays at ten am Eastern on Applecarclay, and Android Auto
• 16:27
  Speaker 1: with the Bloomberg Business app. Listen on demand wherever you
• 16:31
  Speaker 1: get your podcasts, or watch us live on YouTube.
• 16:34
  Speaker 5: Intel coming into the crosshairs of President Trump day, particularly
• 16:39
  Speaker 5: the CEO saying he's got to go. I mean, I
• 16:41
  Speaker 5: have no idea where that came from. I'm guessing Man
• 16:46
  Speaker 5: Deep Sing is read up on this. If nothing else,
• 16:48
  Speaker 5: Man Deep seeing senior tech analyst from Bloomberg Intelligence, President
• 16:52
  Speaker 5: Trump calling for this CEO of Intel to quit not
• 16:55
  Speaker 5: He says he's conflicted. Can you give us the backstory
• 16:58
  Speaker 5: what's going on here? As far as you know?
• 17:00
  Speaker 6: I mean, most likely it has to do with the
• 17:04
  Speaker 6: minority investments that the Intel CEO has in companies within China,
• 17:10
  Speaker 6: and they may have some ties to the Chinese government
• 17:15
  Speaker 6: in some way. And look, he used to be a VC,
• 17:17
  Speaker 6: so this guy has had multiple roles. He used to
• 17:23
  Speaker 6: be the CEO of Cadence, then he was a VC
• 17:27
  Speaker 6: with you know, multiple investments in startups across the globe.
• 17:31
  Speaker 6: So I'm guessing the board Intel board before they appointed
• 17:36
  Speaker 6: him as the CEO, did their due diligence in terms
• 17:39
  Speaker 6: of looking at all these aspects, and to my mind,
• 17:43
  Speaker 6: I mean, it obviously is a surprise that, you know,
• 17:49
  Speaker 6: I mean, his credentials are being questioned here given the
• 17:51
  Speaker 6: reputation he has in the valley.
• 17:54
  Speaker 7: Is the American citizen I'm not sure, probably, but I mean,
• 18:01
  Speaker 7: those are the type of things he would expect the
• 18:03
  Speaker 7: board to do their due diligence on.
• 18:05
  Speaker 6: For a company like Intel, which has had multiple CEOs
• 18:09
  Speaker 6: and clearly is looking for a big turnaround, A lot
• 18:13
  Speaker 6: of people felt this guy had the credentials, you know,
• 18:16
  Speaker 6: in terms of having the experience to turn around a
• 18:19
  Speaker 6: big ship like Intel. And I mean, so far, it's
• 18:23
  Speaker 6: too early to call out how good of a job
• 18:25
  Speaker 6: he was doing. Still early days with his strategy, but
• 18:29
  Speaker 6: clearly he has plans to keep the foundry business and
• 18:34
  Speaker 6: turn around the core chip design business, and he has
• 18:39
  Speaker 6: raised a lot of cash. So I would say still
• 18:42
  Speaker 6: early days with his strategy. But this clearly puts, you know,
• 18:47
  Speaker 6: a wrench in terms of his strategy.
• 18:50
  Speaker 5: Just as per Wiki Wikipedia, it says that he is
• 18:54
  Speaker 5: a Malaysian born American business executive. So that's all I got.
• 18:58
  Speaker 3: Well, something you brought up that they probably you know,
• 19:01
  Speaker 3: people already knew about this. You know, this is no secret.
• 19:05
  Speaker 3: My question is why now? Why bring this up?
• 19:08
  Speaker 2: Now?
• 19:08
  Speaker 3: Why the timing now? And the company has been struggling, right,
• 19:11
  Speaker 3: it's chairs now or down what they're down three percent
• 19:13
  Speaker 3: this morning? But why do you think this has taking
• 19:16
  Speaker 3: place now?
• 19:17
  Speaker 6: I think it's because Senator Tom Cotton, he wrote a
• 19:21
  Speaker 6: letter to the Intel board. They obviously found out some
• 19:25
  Speaker 6: things that he the Senator highlighted, you know, the links
• 19:30
  Speaker 6: to some of the Chinese companies, small companies that had
• 19:34
  Speaker 6: ties to the Chinese government. And I think the board
• 19:39
  Speaker 6: probably has to come up with an answer in terms
• 19:42
  Speaker 6: of the you know, the concerns that were raised by
• 19:44
  Speaker 6: a senator.
• 19:46
  Speaker 5: Has the company responded at all to the senator or
• 19:49
  Speaker 5: the president?
• 19:50
  Speaker 6: I mean they have in terms of the initial response,
• 19:54
  Speaker 6: But to the best of my knowledge, I think the
• 19:58
  Speaker 6: board clearly is defending uh, you know, the credentials of
• 20:04
  Speaker 6: their CEO and uh there's nothing here that would put
• 20:09
  Speaker 6: a question mark around the future of libbutan in terms
• 20:13
  Speaker 6: of running Intel at least for now.
• 20:15
  Speaker 2: Well, that's what I say.
• 20:15
  Speaker 3: Do you think he would would step down? How long
• 20:17
  Speaker 3: has he been in a position?
• 20:18
  Speaker 6: Not few months?
• 20:20
  Speaker 2: Yeah, exactly? Yea.
• 20:21
  Speaker 5: So how is the Intel call here? I mean the
• 20:24
  Speaker 5: stock obviously underperforming, under underperforming pretty dramatically here. It's you know,
• 20:31
  Speaker 5: flat year to date, but you know, relative to Tech
• 20:34
  Speaker 5: that's just losing ground.
• 20:35
  Speaker 6: Germanic they are. And this brings back, you know, some
• 20:39
  Speaker 6: of the discussions we were having a few months back
• 20:43
  Speaker 6: before Libbutan was appointed as a CEO that Intel may
• 20:46
  Speaker 6: be broken down, Qualcom may be looking to buy parts
• 20:51
  Speaker 6: of Intel, and then the foundry business would be separated.
• 20:55
  Speaker 6: I feel if for some reason this CEO has to
• 20:58
  Speaker 6: step down and you know, so someone else is appointed,
• 21:01
  Speaker 6: then it brings all those discussions back into play, because
• 21:05
  Speaker 6: so far, what lib Bhutan had maintained was he wants
• 21:09
  Speaker 6: to keep the foundry business. He wants to turn around
• 21:12
  Speaker 6: through a strategy that involved keeping the chip design and
• 21:16
  Speaker 6: the foundry business together. But if that wasn't to be
• 21:19
  Speaker 6: the case, and if there's somebody new, then I would
• 21:22
  Speaker 6: say that whole aspect around breaking up Intel comes back
• 21:26
  Speaker 6: into play.
• 21:26
  Speaker 7: All right.
• 21:27
  Speaker 5: Stock is down three percent today, so it is feeling
• 21:30
  Speaker 5: the impact of that many i've seen. Thank you so
• 21:32
  Speaker 5: much for joining us, Senior techanost for Bloomberg Intelligence. Joining
• 21:35
  Speaker 5: us here in our studio again. The headline Trump urges
• 21:38
  Speaker 5: quote conflicted Intel CEO ten to resign immediately.
• 21:44
  Speaker 1: This is the Bloomberg Intelligence Podcast, available on Apple, Spotify,
• 21:49
  Speaker 1: and anywhere else you get your podcasts. Listen live each weekday,
• 21:53
  Speaker 1: ten am to noon Eastern on Bloomberg dot com, the
• 21:57
  Speaker 1: iHeartRadio app, tune In, and the Bloomberg Business app. You
• 22:00
  Speaker 1: can also watch us live every weekday on YouTube and
• 22:04
  Speaker 1: always on the Bloomberg terminal